Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Apr 1;10(4):a036939.
doi: 10.1101/cshperspect.a036939.

The Elimination of Hepatitis C as a Public Health Threat

Margaret Hellard  1   2   3   4 , Sophia E Schroeder  1   2 , Alisa Pedrana  1   2 , Joseph Doyle  1   3 , Campbell Aitken  1   2
Affiliations
Review

The Elimination of Hepatitis C as a Public Health Threat

Margaret Hellard et al. Cold Spring Harb Perspect Med. .

Abstract

Hepatitis C virus is a global public health threat, affecting 71 million people worldwide. Increasing recognition of the impact of this epidemic and recent advances in biomedical and technical approaches to hepatitis C prevention and cure have provided impetus for the World Health Organization (WHO) to call for global elimination of hepatitis C as a public health threat by 2030. This work reviews the feasibility of hepatitis C elimination and pathways to overcome existing and potential future barriers to elimination. Drawing on cost-effectiveness modeling and providing examples of successful implementation efforts across the globe, we highlight the resources and strategies needed to achieve hepatitis C elimination. A timely, multipronged response is required if the 2030 WHO elimination targets are to be achieved. Importantly, achieving hepatitis C elimination will also benefit the community well beyond 2030.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
The five strategic directions of the Global Health Sector Strategy on Viral Hepatitis, 2016–2021. (Data in figure adapted from World Health Organization 2016b.)
See this image and copyright information in PMC

References

    1. AASLD-IDSA HCV Guidance Panel. 2018. Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis 67: 1477–1492. 10.1093/cid/ciy585 - DOI - PMC - PubMed
    1. Aitken CK, Agius PA, Higgs PG, Stoové MA, Bowden DS, Dietze PM. 2017. The effects of needle-sharing and opioid substitution therapy on incidence of hepatitis C virus infection and reinfection in people who inject drugs. Epidemiol Infect 145: 796–801. 10.1017/S0950268816002892 - DOI - PMC - PubMed
    1. Alcorn T. 2018. Why Egypt is at the forefront of hepatitis C treatment The Atlantic, May 29, 2018.
    1. Alfaleh FZ, Nugrahini N, Matičič M, Tolmane I, Alzaabi M, Hajarizadeh B, Valantinas J, Kim DY, Hunyady B, Abaalkhail F, et al. 2015. Strategies to manage hepatitis C virus infection disease burden—volume 3. J Viral Hepat 22(Suppl 4): 42–65. 10.1111/jvh.12474 - DOI - PubMed
    1. Andrieux-Meyer I, Cohn J, de Araújo ES, Hamid SS. 2015. Disparity in market prices for hepatitis C virus direct-acting drugs. Lancet Glob Health 3: e676–e677. 10.1016/S2214-109X(15)00156-4 - DOI - PubMed

Substances